Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.55 |
| ▸ | AR | P10275 | 11/20 | 0.48 |
| ▸ | PGR | P06401 | 5/20 | 0.48 |
| ▸ | F2RL3 | Q96RI0 | 3/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | F2R | P25116 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17576255 | 0.81 | MAPT (0.63) | MAPTF2RL3MEN1LMNAF2R | |
| SCHEMBL20568611 | 0.79 | MAPT (0.57) | MAPTF2RL3MEN1LMNAF2R | |
| SCHEMBL31169742 | 0.79 | MAPT (0.57) | MAPTF2RL3MEN1LMNAF2R | |
| SCHEMBL155568 | 0.78 | MAPT (0.83) | MAPTF2RL3MEN1LMNAF2R | |
| SCHEMBL30600488 | 0.78 | MAPT (0.83) | MAPTF2RL3MEN1LMNAF2R | |
| SCHEMBL21957297 | 0.77 | AR (0.50) | ARPGR | |
| SCHEMBL23610702 | 0.77 | MAPT (0.51) | MAPTF2RL3MEN1LMNAF2R | |
| SCHEMBL21978549 | 0.76 | AR (0.49) | ARPGR | |
| SCHEMBL6077653 | 0.76 | AR (0.52) | ARPGRMEN1KMT2ANPSR1 | |
| SCHEMBL20568458 | 0.75 | MAPT (0.52) | MAPTF2RL3MEN1LMNAF2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7074933-B2 | Urea and thiourea derivatives | WARNER LAMBERT COMPANY LLC (US) | 2006-07-11 | — | — | US | disclosed |
| EP-1603882-A2 | UREA AND THIOUREA DERIVATIVES | Warner-Lambert Company LLC (US) | 2005-12-14 | — | — | EP | disclosed |
| US-20040266820-A1 | Urea and thiourea derivatives | DU DANIEL Y (US) | 2004-12-30 | — | — | US | disclosed |
| WO-2004072044-A2 | UREA AND THIOUREA DERIVATIVES | WARNER-LAMBERT COMPANY LLC (US) | 2004-08-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040266820-A1 | Urea and thiourea derivatives | SHBG, ZP1, ZYX | MAPT 878/4885AR 25/4885PGR 1108/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.